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Abstract
Despite major advances in early revascularization techniques, cardiovascular diseases are still the leading cause of death
worldwide, and myocardial infarctions contribute heavily to this. Over the past decades, it has become apparent that
reperfusion of blood to a previously ischemic area of the heart causes damage in and of itself, and that this ischemia
reperfusion induced injury can be reduced by up to 50% by mechanical manipulation of the blood flow to the heart. The
recent discovery of remote ischemic preconditioning (RIPC) provides a non-invasive approach of inducing this
cardioprotection at a distance. Finding its endogenous mediators and their operative mode is an important step toward
increasing the ischemic tolerance. The release of humoral factor(s) upon RIPC was recently demonstrated and several
candidate proteins were published as possible mediators of the cardioprotection. Before clinical applicability, these
potential biomarkers and their efficiency must be validated, a task made challenging by the large heterogeneity in reported
data and results. Here, in an attempt to reproduce and provide more experimental data on these mediators, we conducted
an unbiased in-depth analysis of the human plasma proteome before and after RIPC. From the 68 protein markers reported
in the literature, only 28 could be mapped to manually reviewed (Swiss-Prot) protein sequences. 23 of them were monitored
in our untargeted experiment. However, their significant regulation could not be reproducibly estimated. In fact, among the
394 plasma proteins we accurately quantified, no significant regulation could be confidently and reproducibly assessed. This
indicates that it is difficult to both monitor and reproduce published data from experiments exploring for RIPC induced
plasma proteomic regulations, and suggests that further work should be directed towards small humoral factors. To simplify
this task, we made our proteomic dataset available via ProteomeXchange, where scientists can mine for novel potential
targets.
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Introduction
Remote ischemic preconditioning (RIPC) is an emerging
treatment for reducing ischemia reperfusion injury (IRI) in the
heart. Several proof-of-concept studies and small randomized
controlled trials have demonstrated that the human heart is
amenable to RIPC [1–5]. Recently, it was also reported that 3
cycles of 5 min upper arm ischemia substantially reduced
myocardial injury after coronary artery bypass graft in large pools
of patients. This was demonstrated by a significant decrease in
cardiac troponin I (cTnI) release, significantly improving prognosis
with a reduction in mortality in the group receiving RIPC
compared to controls [6].
The signaling pathway of RIPC in the human heart is just
starting to be uncovered [7], but how the RIPC stimulus is
transferred from the arm to the heart remains unclear. Compelling
preclinical evidence suggests communication via one or more
unknown humoral factors: First, it seems that a period of
reperfusion after the RIPC stimulus is required for protection,
suggesting that wash-out of blood borne factors and transport to
the site of protection is involved [8–10]. Secondly, it was
demonstrated that effluent from preconditioned hearts could
transfer the protection to naı¨ve recipient hearts and that the
protection is mediated via small, unknown hydrophobic factors of
protein nature between 3.5 and 15–30 kDa [11–16]. Moreover,
the fact that this humoral factor is effective at a remote location
after dilution in blood or perfusion fluid, hints at a large
concentration change which should be detectable by modern
proteomic techniques.
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In fact, several proteins were recently found to be regulated
after RIPC, paving the way for potential use of these cardiopro-
tective compounds in the clinic. Notably, Hepponstall et al.
conducted an ambitious study where 806 differentially expressed
peptides were identified after RIPC. Among them, 133 could be
mapped to 48 protein sequences [17]. In addition, 2D gel
experiments reported 33 regulated spots with 6 identifiable
proteins. Surprisingly, only one of the given protein accession
numbers could be found in both the mass spectrometry and the
2D gel result sets. Subsequently, Pang et al. found 14 proteins to
be differentially regulated by RIPC and validated these findings by
Western blotting [18]. Notably, only one of the accessions
reported, Gelsolin (UniProt accession number P06396), could be
mapped to those published by Hepponstall et al. Additionally,
albeit with different sequences, both studies underlined the
regulation of Apolipoprotein A-I. However, Pang et al. found this
protein to be down-regulated, while Hepponstall et al. found it
down-regulated using gels and up-regulated when applying a gel
free technique in the same study. The latter result is in
concordance with the study of Hibert et al. showing a 30% up-
regulation of Apolipoprotein A-I, postulating it to be the principal
factor behind RIPC mediated cardioprotection [19]. Later on,
however, Hilbert et al. published another report where this protein
appeared not to be regulated, but seven other related proteins
presented a Mann-Whitney test p-value ,0.05 [20]. Notably, no
protein passed a more stringent 0.01 threshold and all proteins
showed moderate regulations (between 0.58:1 and 1.2:1), consis-
tently below the two fold change regulation level generally used in
biology. The results of Davidson et al. suggested SDF-1a to be the
main mediator of RIPC, presumably communicating the cardio-
protection via SDF-1a/CXCR4 signaling [21]. Importantly,
Przyklenk [22] criticized the latter study for its limitations, as the
plasma levels of SDF-1a should have been monitored both before
and after the RIPC stimulus, thereby failing to validate the factor
as a mediator of RIPC.
Discovery studies ‘‘often significantly overestimate their find-
ings’’ as claimed by Gosho et al. [23]. Consequently, prior to
clinical testing, protein markers must be validated, preferably
using targeted mass spectrometry based proteomics [24]. For that,
quantitative assays are built in order to target and quantify the
compounds of interest. Setting up such an assay requires
experimental data on the digestion, peptide elution, ionization,
and fragmentation profile of the targeted protein. This informa-
tion is, however, not available from any of the mentioned mass
spectrometry datasets. Notably, they are not available in public
repositories, despite this being standard publication guidelines in
proteomics [25,26]. In fact, the peptide information is not
available and in the case of Hepponstall et al., not even the
estimated protein ratios are reported.
The disagreement in the literature, even in studies from the
same group or within the same study, together with the lack of
provided information, show the striking need for a transparent
proteomic dataset stringently monitoring the proteomic changes
induced by RIPC. Here, we present a quantitative in depth
sequencing of the plasma proteome before and after RIPC. Six
healthy donors underwent RIPC according to the protocol used in
consensus with the literature and whose efficiency has been long
established. In contrast to previously reported studies, the digested
plasma samples were multiplexed using isobaric tags and
fractionated, thereby limiting inter-sample artifacts and dramat-
ically increasing sample coverage. The protein identification and
quantification was achieved using open source software applying
stringent quality criteria to avoid reporting artifact regulations.
The acquired raw data was deposited to the ProteomeXchange
consortium [27] together with identification results, and can
thereby freely be accessed, inspected and even reprocessed to
better plan further experiments [28].
Materials and Methods
This study was approved by the regional ethics committee for
medical and health research in Western Norway (REK 2010/
1642-1). Written informed consent was obtained from all
participants and the study conformed to the principles in the
declaration of Helsinki. Six healthy adult male donors aged 2962
years old (mean 6 SD), not on any medication, underwent the
RIPC protocol which consisted of 3 cycles of 5 min upper arm
ischemia alternating with 5 min reperfusion (Figure 1). All subjects
rested upright on a bench for 15 min before ischemia was induced
by inflating a blood pressure cuff to 200 mmHg. Venous blood
samples were collected from the ipsilateral arm after 14 min of rest
in the beginning, and at 1 and 4 min into each reperfusion period.
Blood samples were collected in K2 EDTA-coated tubes
(Vacutainer, BD). Samples were centrifuged at 1,500 rcf at 4uC
for 15 min within 30 min after sampling. 1.5 ml plasma was
transferred to Eppendorf tubes before a second centrifugation at
15,000 rcf at 4uC for 15 min to remove any cell contaminants or
cell fragments. ,90% of the clear supernatant was removed using
a 1 ml pipette and stored at 280uC. The whole process from
sampling to freezing of each individual sample took less than
75 min. Samples from 1 and 4 min of each of the reperfusion
periods were pooled, resulting in 12 samples: a sample before
(control) and after RIPC for each of the six individuals.
Chemicals
Trypsin was purchased from Promega. N-octyl-b-D-glycopyr-
anoside (NOG), acetonitrile (ACN), formic acid (FA), ammonium
formate and water were purchased from Sigma-Aldrich. Water
and ACN were of HPLC quality.
Abundant protein depletion and concentration
20 ml of plasma from each sample was depleted using a human
Multiple Affinity Removal System (MARS Hu-14)
4.6 mm650 mm LC column (Agilent Technologies) according
to the protocol provided by the supplier, using a Dionex 3000-
series LC system. The MARS column depletes the plasma of
albumin, IgG, antitrypsin, IgA, transferrin, haptoglobin, fibrino-
gen, alpha-2-macroglobulin, alpha-1-acid glycoprotein, IgM,
apolipoprotein AI, apolipoprotein AII, complement C3 and
transthyretin. The protein depleted plasma samples were concen-
trated using 3 kDa ultracentrifugation filters (Amicon Ultra-4,
Millipore, Bedford, MA) pre-treated with 0.1% NOG.
Protein digestion and iTRAQ labeling
The entire depleted protein sample was reduced, cysteine
blocked, trypsin digested (1:20, trypsin:protein, w/w), iTRAQ
labeled (114, 115, 116 and 117) and combined according to the
protocol using the chemicals provided (AB Sciex). The iTRAQ 4-
Plex kit allowed us to multiplex two conditions from two donors
per kit, resulting in three parallel experiments as detailed in
Table 1. Both conditions (before and after RIPC) followed the
exact same downstream workflow for every individual.
Mix-mode fractionation
iTRAQ labeled peptides were fractionated into 60 fractions
using a mixed-mode (MM) reversed phase anion exchange (RP-
AX) Sielc Promix column as described by Philips et al. [29] (MP-
10.250.0530, 1.06250 mm, 5 mm, 300 A˚, Sielc Technologies,
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Prospect Heights, Illinois) coupled to an Agilent 1260 series LC
system (Agilent Technologies, Palo Alto, CA). The iTRAQ labeled
peptides were reconstituted in 20 mM ammonium formate, 3%
ACN (buffer A) and loaded on the column in 85% buffer A for
10 minutes at a flowrate of 50 ml/min. The peptides were eluted
from the column increasing the contents of buffer B (2 mM
ammonium formate, 80% ACN, pH 3.0), from 15% to 60% in
35 minutes and further to 100% buffer over 10 minutes. Buffer B
was held constant for 5 minutes before the column was
equilibrated for 10 minutes in 85% buffer A. The fractions from
the first 10 minutes of the gradient were discarded.
LC-MS/MS analyses
Fifty fractions from the MM RP-AX separation from each
sample were analyzed on an LTQ-Orbitrap Velos Pro (Thermo
Scientific) coupled to a Dionex Ultimate NCR-3000RS LC
system. The fractions were dissolved in 1% FA and trapped on
the pre-column (Dionex, Acclaim PepMap 100, 2 cm675 mm i.d,
3 mm C18 beads) in buffer A (2% ACN, 0.1% FA) at a flowrate of
5 ml/min for 5 minutes before separation by reverse phase
chromatography (Dionex, Acclaim PepMap 100, 15 cm675 mm
i.d., 3 mm C18 beads) at a flow of 280 nL/min. The fractions were
run on three nano LC gradients: The first fifteen fractions were
run on a LC gradient consisting of a gradient starting at 5% buffer
B (90%ACN, 0.1% FA) ramping to 12% buffer B over 55 minutes
(5–60 min), the gradient was subsequently ramped to 30% buffer
B in 30 minutes (60–90 min), increased to 90% B in 10 minutes
(90–100 min), held for 5 minutes (100–105 min) followed by
ramping to 5% buffer B for 3 minutes (105–108) and equilibration
of the column in 12 minutes (108–120); fractions 16–35 were
separated on the following LC gradient: 0–5.0 minutes 5% buffer
B, 5.0–5.5 minutes 8% buffer B, 5.5–60 minutes 20% buffer, 60–
90 minutes 35% buffer B; the last fractions (36–50) were separated
using the following gradient: 0–5.0 minutes 5% buffer B, 5.0–
5.5 minutes 8% buffer B, 5.5–90 minutes 40% buffer. The last
part of the nano LC gradient is similar for all three gradients.
The mass spectrometer was operated in data-dependent-
acquisition (DDA) mode to automatically switch between full scan
MS and MS/MS acquisition. The instrument was controlled by
Tune 2.6.0 and Xcalibur 2.1. Survey full scan MS spectra (from
m/z 300 to 2,000) were acquired in the Orbitrap with resolution
R = 60,000 at m/z 400 (after accumulation to a target value of
1E6 in the linear ion trap with maximum allowed ion accumu-
lation time of 500 ms). The 7 most intense eluting peptides above
an ion threshold of 1,000 counts and charge states 2 or higher,
were sequentially isolated in the high-pressure linear ion trap to a
target value of 5E5 at a maximum allowed accumulation time of
1,000 ms, and isolation width maintained at 2 Da. Fragmentation
in the Higher-Energy Collision Dissociation (HCD) cell was
performed with a normalized collision energy of 40%, and
activation time of 0.1 ms. Fragments were detected in the
Orbitrap at a resolution of 7,500 with first mass fixed at m/z 100.
Data analysis
All RAW data were transformed into mgf peak lists using the
ProteoWizard software [30] package version 2.2.2954. The
obtained peak lists were searched with OMSSA [31] version
2.1.9 and X!Tandem [32] Cyclone 2013.2.01.1 using SearchGUI
Figure 1. Experimental protocol. A peripheral venous catheter was inserted in the cubital fossa of subject for blood sampling. The subject rested
for 14 min reclined on a bench before the baseline sample was drawn. The blood pressure cuff was inflated to 200 mmHg for 5 min before being
released. Blood samples were drawn at 1 and 4 min into reperfusion from the ipsilateral arm. Blood samples were centrifuged to collect plasma which
was stored at 280uC. Before analysis, all six reperfusion samples were pooled for each subject.
doi:10.1371/journal.pone.0109279.g001
Table 1. Repartition on every iTRAQ channel of the samples at baseline and after RIPC for the six donors.
iTRAQ Channel Experiment 1 Experiment 2 Experiment 3
114 Donor 1 baseline Donor 3 RIPC Donor 5 baseline
115 Donor 1 RIPC Donor 3 baseline Donor 5 RIPC
116 Donor 2 baseline Donor 4 RIPC Donor 6 baseline
117 Donor 2 RIPC Donor 4 baseline Donor 6 RIPC
doi:10.1371/journal.pone.0109279.t001
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[33] version 1.12.2. Peak lists were searched against a concate-
nated target/decoy [34] version of the human complement of the
UniProtKB/Swiss-Prot database [35] (downloaded on September
2012). The decoy sequences were created by reversing the target
sequences in SearchGUI. Search settings were as follows: Trypsin
with a maximum of 2 missed cleavages; 10 ppm as MS, 0.6 Da as
MS/MS tolerances, respectively; fixed modifications: methylthio
of Cys (+45.987721 Da) and iTRAQ on Lys and peptide N-term
(+144.105918 Da); and variable modifications: oxidation of Met (+
15.994915 Da) and iTRAQ on Tyr (+144.105918 Da). All other
OMSSA or X!Tandem settings were kept at the default values set
in SearchGUI. Peptides and proteins were inferred from the
search engine results using PeptideShaker (http://peptide-shaker.
googlecode.com) [36]. Peptide to Spectrum Matches (PSMs),
peptides and proteins were validated at a stringent 1% FDR
estimated using the decoy hits. The mass spectrometry proteomics
data have been deposited to the ProteomeXchange Consor-
tium(http://proteomecentral.proteomexchange.org) [27] via the
PRIDE partner repository [37,38] with the dataset identifier
PXD000605 and DOI 10.6019/PXD000605.
For every validated protein, the iTRAQ reporter ions were
extracted from spectra of validated PSMs and deisotoped using the
isotope abundance matrix [39]. Intensities were normalized using
the median intensity in order to limit the ratio deviation [40] and
peptide and protein ratios were estimated using maximum
likelihood estimators [41]. Ratios were log2 converted and
normalized to the median to avoid inter-sample bias. Only those
proteins presenting two or more validated and quantified peptides
were retained for the quantitative analysis. Standard contaminants
as well as all proteins with known affinity to the antibodies in the
MARS column were excluded from downstream statistical
analysis. A paired two-sided t-test was conducted on protein ratios
using a p-value threshold of 0.01. Subsequently, in order to
distinguish RIPC specific regulations from random biological
variability, an asymmetric normal distribution was drawn from the
background ratios (calibrated on the median and 634.1 percen-
Figure 2. Analysis workflow. Plasma samples were depleted by a MARS Hu-14 column and subsequently concentrated by 3 kDa
ultracentrifugation filters. Next, samples were reduced, cysteine blocked and trypsin digested before iTRAQ labeling. The iTRAQ labeled peptides
were fractioned into 60 fractions using a mixed-mode reverse phase anion exchanger. Finally, fractions were analyzed on an LTQ-Orbitrap Velos Pro
connected to a Dionex Ultimate NCR-3000RS LC system.
doi:10.1371/journal.pone.0109279.g002
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tiles) and only those proteins having a probability ,1% to be
derived from the background were considered confidently
regulated. Finally, protein abundance indexes were estimated
using spectral counting where the spectral counting index is simply
the number of validated PSMs divided by the protein molecular
weight [42].
Results
The plasma proteome from six healthy donors was compared at
baseline and after RIPC as illustrated in Figure 1 and 2. In total,
727 proteins were confidently identified (,1% FDR). Among
them, 409 proteins could be accurately quantified by two or more
unique peptides. Of these, 393 remained after exclusion of known
contaminant and depletion-affected proteins, and are listed in
Table S1. These 393 accurately quantified plasma proteins
showed accurate and reproducible stability: 388 (98.7%) presented
a fold change between 0.91:1 and 1.1:1, which is in accordance
with the known technical variability of iTRAQ quantification
reported in the literature [43]. In order to assess the relevance of
the regulations, the quantified proteins were classified into four
categories (as detailed in Table S1): (A) proteins with low
variability among donors (t-test passed) and confident regulation
to the background (no protein); (B) low donor variability but no
confident regulation to the background (4 proteins); (C) high donor
variability (t-test failed) but confident regulation to the background
(42 proteins); and (D) high donor variability (t-test failed) and no
confident regulation to the background (347 proteins). These
proteins are plotted in Figure 3 and 4. Notably, no protein was
validated by both statistical tests (category A).
Four proteins had a significant p-value (,0.01) between the
baseline and RIPC samples for the six subjects examined (category
B; Kallistatin, Complement C2, Lactoylglutathione lyase (GLO1),
and Cysteine-rich secretory protein 3 (CRISP-3))(Table S1). The
fold changes for these, however, were very low (,10% change).
We considered changes below 20% to be within what can be
explained by the technical variability of the analytical approach.
This was corroborated by the statistical analysis, showing no
confident regulation to the background. Interestingly, all highly
regulated proteins were detected in a much lower abundance (see
Figure 4) and failed the t-test (p-value.0.01), suggesting that these
cannot be trusted for clinical application.
In contrast, high ratios were systematically found for contam-
inants and proteins affected by depletion. Remarkably, the
remaining amount of proteins targeted by the MARS hu-14
depletion column was consistently less abundant in RIPC samples,
hinting at a systematic artifact in the depletion procedure. Among
them, fibronectin, previously reported to be regulated after RIPC
has been identified in the bound fraction after MARS hu-14
depletion [44]. Fibronectin was confidently regulated to the
background (ratios of 0.62:1) in close agreement with Apolipo-
protein A-I (ratio of 0.61:1) and Haptoglobin (ratio of 0.63:1), both
also targeted by the MARS column. In conclusion, we cannot rule
out that the difference in relative abundance measured for these
proteins are not simply protocol related. On the other hand, our
ability to quantify these potential experimental artifacts demon-
strates the reliability of the quantification procedure and rules out
the hypothesis that regulations were systematically lost along the
workflow.
Discussion
RIPC of the upper arm is an easy, practical and non-invasive
way of inducing protection from ischemia reperfusion induced
injury (IRI) in the heart, and the remote ischemic conditioning
stimulus can even be applied during or immediately after an
ischemic insult (as reviewed in [45–47]). The protocol used in the
present study was chosen for its proven clinical efficiency: It was
demonstrated to reduce the release of troponins (marker for
cardiac damage) [3–5] and improve survival [6] after coronary
artery bypass graft surgery. Shimizu et al. used a human RIPC
protocol of 465 min, sampled venous blood before and after the
RIPC intervention, and demonstrated that both whole plasma and
plasma dialysate ,15 kDa could reduce IRI in the isolated rabbit
heart [15]. This protocol is comparable, but not identical, to the
one used for the proteomic studies mentioned above, ensuring
comparability between the results.
Table S2 gives a generated list of all biomarkers found in the
literature, in addition to the ones identified in this study, including
the measured ratios and t-test results. As detailed in the
introduction, Hepponstall et al. [17] report 53 regulated proteins
after RIPC. The provided accession numbers were mapped to
UniProt entries using the Picr service of the European Bioinfor-
matics Institute [48], leading to mapping of only 14 Swiss-Prot
sequences – all other sequences having low or no evidence. 11 of
them were confidently quantified in our study (see Table S2). Only
Fibronectin (t-test passed) and Haptoglobin (t-test failed) were
found to be regulated. However, the regulation of these factors
may be experimental artifacts as discussed earlier.
From the 14 proteins reported as regulated by Pang et al. [18],
13 could be mapped to Swiss-Prot accessions, and 12 were
accurately quantified in our experiment. Among these, only
Apolipoprotein A-I was found to be regulated (0.61:1 ratio).
However, as detailed already, it is one of the targets of the
depletion procedure. As a result, it is impossible to validate
whether this controversial protein is actually regulated by RIPC or
whether the up- and down-regulations reported in the literature
may be due to experimental artifacts.
Furthermore, we did not quantify SDF-1a, a purported
signaling molecule of RIPC [21,22]. Nor did we identify a single
of its peptides. This protein is a good example of the challenges
posed when identifying RIPC mediators, as peptide based protein
quantification heavily relies on the ability to detect at least two
peptides, which can become defying for small proteins. It is
important to note that most of the reported potential mediators of
RIPC mediated cardioprotection do not meet the mass expecta-
tion (,30 kDa). More experimental data are, thus, necessary to
assess the role of SDF-1a in RIPC.
In our study, we identified 4 proteins (category B) to be
significantly regulated according to the t-test, but showed no
confident regulation to the background; Kallistatin, Complement
C2, Lactoylglutathione lyase (GLO1), and Cysteine-rich secretory
protein 3 (CRISP-3) (Table S1). Despite claiming an overall
negative study outcome, as no factors were released in abundance
and confidently regulated to the background, it is perhaps timely
to consider whether RIPC might be mediated by a consortium of
slightly regulated humoral factors, acting on one or several
signalling networks, which in concert induce protection. Interest-
ingly, we identify 3 proteins (kallistatin, kallikrein, and kininogen-
1) that might inter-relate in the kallikrein-kinin signalling pathway.
Of further interest, and adding to the complexity, Complement 2
as part of the complement system may also exerts cross-talk with
proteins of the kinin-generating systems. The 4 category B proteins
will be discussed further below.
Kallistatin, in particular, proves to be a very interesting
candidate in terms of cytoprotective capabilities (UniProt accession
P29622, 48 kDa, p-value 0.002, fold-change 1.04). Chao and co-
workers identified kallistatin as a tissue kallikrein binding protein
(KBP) and a unique serine proteinase inhibitor (serpin) [49]. Later,
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kallistatin has been ascribed many other functions unrelated to its
interaction with tissue kallikrein, including lowering blood
pressure, vasodilatation, preventing cardiac remodelling and
offering protection against cardiovascular injuries by preventing
apoptosis, oxidative stress, and inflammation [50–54]. Moreover,
the effects of kallistatin seems to be mediated via pro-survival
PI3K/Akt/NO dependent signalling, and is postulated to be
activated by a yet unidentified kallistatin specific cell surface
receptor or binding protein [52]. Kallistatin may also act as an
inhibitor of kallikrein [49], and we found kallikrein to be slightly
down-regulated in our data (UniProt accession P03952, category
D, 71 kDa, p-value 0.014, fold change 0.96). Kallikrein may be
activated by lowered plasma pH [55] due to flow restriction
imposed by the ischemic conditioning cycles, which in turn can
reduce kinin breakdown, enhance bradykinin (BK) formation [56–
58], and inhibit BK degradation [59]. We also observed that the
MK-RPPGFSPFR-SS peptide located at amino-acids 381 to 389
of Kininogen-1 (UniProt accession P01042, catgory D, 72 kDa)
was recorded with a 10 times increase in the number of spectra
when compared to the median of the peptides for this protein. The
peptide may be a product of Kininogen-1 degradation. Plasma
and tissue kallikreins converts kiniogens to produce vasoactive
kinin peptides, such as bradykinin and lys-bradykinin. BK is
known to exert anti-ischemic effects and for being a possible
mediator of ischemic preconditioning, although the peptide
presence could not directly be related to RIPC in our experiment
(ratio of 1.02:1, p-value of 0.43). But kinin receptors were
previously shown to be influenced by RIPC [60], so monitoring
kininogen degradation products might be a promising approach
elucidating the RIPC mechanism.
The complement system, which is part of the innate humoral
immune system, was slightly up-regulated (UniProt accession
P06681, 83 kDa, p-value 0.003, fold-change 1.02). Weissman et al.
[61] demonstrated that complement components are deposited in
ischemia reperfused myocardium. In addition, animal models of
IR in other organ systems like the gut, kidney, and skeletal muscle
indicate that the complement system is a key mediator of IRI [62–
67]. However, the precise mechanism of complement activation in
ischemic tissue has not been clearly elucidated due to the lack of
appropriate experimental models, restricted knowledge of the
molecular processes causing complement activation during hyp-
oxia in cells, and how it exerts cross-talk between different
complement activation pathways [68]. Despite the fact that
complement activation during IR is associated with cellular
injuries; it is intriguing that the complement system exerts cross-
talk with proteins of the kinin generating systems [69].
Lactoylglutathione lyase (also known as glyoxalase I or GLO1)
was slightly down-regulated after RIPC (UniProt accession
Q04760, 23 kDa, p-value 0.005, fold-change 0.92). Glyoxalase 1
(GLO1) in combination with glyoxalase 2 and the co-factor
gluthatione constitute the glyoxalase system, which is responsible
for the detoxification of methylglyoxal (MG) [70]. MGs are highly
reactive metabolites of glucose degradation pathway, protein and
fatty acid metabolism. MG itself is cytotoxic and pro-apoptotic.
Figure 3. Volcano plot. The significance of the relative regulation of 394 proteins was inspected using (1) a paired two-sided t-test (y axis) and (2)
by estimating the probability for the regulation derived from the background (x axis). Proteins are clustered into four categories based on the
statistical test passing the threshold (see text for details).
doi:10.1371/journal.pone.0109279.g003
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GLO1 might be a key factor for detoxifying MG and protecting
organs against IR injury [71], and may also prevent hyperglyce-
mia-induced diabetic complications [72,73]. Despite a potential
protective role of GLO1, it appears down regulated in our study,
and could, thus, be unrelated to the cardioprotective properties of
RIPC mediating humoral factors.
Our data also identified glycoprotein human cysteine-rich
secretory protein 3 (CRISP-3) as slightly up-regulated (UniProt
accession P54108, 28 kDa, p-value 0.007, fold-change 1.06).
CRISP-3 is believed to play a role in innate immunity. High levels
of human CRISP-3 was found in plasma bound to a1-1B-
glycoprotein (A1BG-like) (a plasma protein of unknown function)
[74]. The A1BG–CRISP-3 complex is thought to inhibit the toxic
effect of snake venom metalloproteinases or myotoxins. Udby et al.
suggests that the A1BG–CRISP-3 complex displays a similar
function in protecting the circulation from a potentially harmful
effect of free CRISP-3, although the overall function of CRIPS-3 is
unclear [74]. Cardiac related effects of CRISP-3 has not been
described in the literature as of yet. We also identified the
proposed A1BG binding partner in our data (P04217; category D;
54 kDa; p-value 0.16; fold change 1.02).
It is crucial to consider that even with the best analytical
approaches available today, there is a limit to how many proteins
that can be identified and quantified in plasma. Notably, isoforms,
posttranslational modifications and degraded proteins are a vast
field of investigation and future experiments might, thus, be
directed at other targets in blood. Moreover, we decided to pool all
the reperfusion samples for each individual, making sure all
potential relevant proteins were present in the sample. However,
pooling of the samples may have masked possible time-dependent
RIPC induced protein/mediator alterations, in addition to
averaging the relative abundance of potential candidate proteins.
It also reduces the ability to monitor changes occurring after a
single conditioning cycle only. Future work might, thus, improve
the time resolution of the experiment.
In addition to technical analytical factors as described here,
other aspects of the RIPC procedure such as the number of cycles
and stimulus site should be considered when mining for blood
borne humoral factors. Loukogeogakis et al. elegantly demon-
strated a dose-response effect with regards to both site and number
of cycles, when exploring for the protective effect of RIPC on
endothelial IRI of the arm. The maximum protective effect was
obtained with 3 cycles of IR of the arm and at least 2 cycles of the
leg [75]. This study is complemented by the study of Hong et al.,
suggesting that the protective effects of RIPC by lower limb
ischemia are greater than those induced by upper limb ischemia
[76]. The reason that fewer cycles of the lower limb induced
protection may possibly be due to a larger lower limb mass leading
to greater release of humoral factors. However, according to a very
recent systematic review and meta-analysis [77], it is clear that the
optimal RIPC stimulus has not been demonstrated, and it is
unknown whether upper or lower limb ischemia is superior.
Furthermore, the most favorable timing/duration of the stimulus is
unclear. Once the optimal stimulus algorithm, site and timing for
the RIPC procedure and more certain indications of the RIPC
mediated humoral factor(s) mediating protection are established, it
will be timely to compare the healthy plasma RIPC proteome to
that of diseased patient populations. Furthermore, comparison of
age-matched young and old, male and females might also
delineate possible and important age and sex differences.
Figure 4. Protein regulation vs. abundance index. The protein regulation is plotted against the abundance index and every protein is classified
according to the result of the statistical tests.
doi:10.1371/journal.pone.0109279.g004
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In conclusion, using shotgun quantification techniques, the
detectable portion of the plasma proteomes of six healthy adult
males was stable after remote ischemic preconditioning, and in
contrast to the literature, no significant changes were identified,
other than those that appeared to be related to contaminants or
the analytical process itself. Four proteins did, however, show low
donor variability (passed the t-test) but was not confidently
regulated to the background. One way of moving forward could
be to increase the workflow sensitivity, with regards to time or
biological targets, e.g. by selecting on hydrophobicity and size.
Supporting Information
Table S1 The complete table of experimental data from
all three iTRAQ experiments. All proteins we identified were
classified into four categories based on two statistical tests: (A)
proteins with low variability among donors (t-test passed) and
confident regulation to the background (no protein); (B) low donor
variability but no confident regulation to the background (4
proteins); (C) high donor variability (t-test failed) but confident
regulation to the background (42 proteins); and (D) high donor
variability (t-test failed) and no confident regulation to the
background (347 proteins).
(XLSX)
Table S2 A list of all biomarkers found in the literature,
in addition to the ones identified in this study. This
includes their measured ratios and t-test results.
(XLSX)
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